EnteroMedics touts study showing improved weight loss in moderate obesity patients

EnteroMedics (NSDQ:ETRM) today released data from the ReCharge study of its vBloc Neurometabolic Therapy in patients with moderate obesity, touting 74% greater weight loss with vBloc therapy compared to a sham control.

Full results form the St. Paul, Minn.-based company’s trial were published in the journal Obesity Surgery.

“Results observed in the moderately obese population provide strong support for vBloc Therapy’s application within this subgroup of patients, many of whom are not willing to undergo, or not appropriate for, more aggressive surgical interventions. We look forward to further understanding how vBloc performs in this population, as we continue to review long-term data derived from ReCharge and other vBloc studies,” chief medical officer Dr. Scott Shikora said in a press release.

Patients treated with vBloc reported an average weight loss of 33% of excess weight at 12 months, while 75% of patients lost at least 20% of their excess weight and 25% lost at least 50%, EnteroMedics said.

“vBloc Therapy represents a safe and well-tolerated, neuroscience-based approach for the treatment of patients with moderate obesity and related comorbid conditions. Its ability to foster clinically meaningful weight loss safely, without changes in anatomy, establishes vBloc as a much needed anatomy sparing alternative to existing treatment options,” Dr. John Morton of the Stanford University School of Medicine said in prepared remarks.

The ReCharge trial is a prospective, randomized, double-blind, sham-controlled trial of the vBloc Neurometabolic Therapy which enrolled 239 patients with obesity, the company said.

“The moderately obese data from ReCharge, and their publication in Obesity Surgery, highlights an important and meaningful segment of the obesity population for which vBloc Therapy fills a significant unmet need, delivering a safe, effective, durable treatment for obesity and its comorbidities. This population is an important area of focus for our commercial efforts, and one where we believe we can deliver differentiated value to the patient, their physician and payers,” CEO Dan Gladney said in a prepared statement.

In January, EnteroMedics said it closed the 2nd tranche of the $25 million senior amortizing convertible notes offering it announced last November, bringing in $11 million.

At the initial closing in November the company received $1.5 million, with a 3rd tranche of $12.5 million scheduled in 45 days, the St. Paul, Minn.-based company said.

Enteromedics said it will use net proceeds from the offering to continue the commercialization of its Maestro Rechargeable System, for clinical and product development and as working capital,according to an SEC filing posted today.

The post EnteroMedics touts study showing improved weight loss in moderate obesity patients appeared first on MassDevice.

from MassDevice http://ift.tt/1PSuOZC